HomeCompareMTEM vs MO

MTEM vs MO: Dividend Comparison 2026

MTEM yields 2000000.06% · MO yields 6.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MTEM wins by $4.8792278646347776e+39M in total portfolio value
10 years
MTEM
MTEM
● Live price
2000000.06%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.8792278646347776e+39M
Annual income
$4,878,748,002,861,388,000,000,000,000,000,000,000,000,000,000.00
Full MTEM calculator →
MO
Altria Group Inc.
● Live price
6.27%
Share price
$67.02
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$28,968.54
Full MO calculator →

Portfolio growth — MTEM vs MO

📍 MTEM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMTEMMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MTEM + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MTEM pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MTEM
Annual income on $10K today (after 15% tax)
$170,000,005.10/yr
After 10yr DRIP, annual income (after tax)
$4,146,935,802,432,179,400,000,000,000,000,000,000,000,000,000.00/yr
MO
Annual income on $10K today (after 15% tax)
$532.68/yr
After 10yr DRIP, annual income (after tax)
$24,623.26/yr
At 15% tax rate, MTEM beats the other by $4,146,935,802,432,179,400,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MTEM + MO for your $10,000?

MTEM: 50%MO: 50%
100% MO50/50100% MTEM
Portfolio after 10yr
$2.4396139323173888e+39M
Annual income
$2,439,374,001,430,694,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

MTEM
Analyst Ratings
6
Buy
1
Hold
1
Sell
Consensus: Buy
Altman Z
-24.9
Piotroski
2/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-8.6% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MTEM buys
0
MO buys
11
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$MO▲ Buy$1,000 - $15,0002025-08-04
Sheri Biggs🏢 House$MO▼ Sell$1,001 - $15,0002025-03-19
Pete Sessions🏢 House$MO▼ Sell$1,001 - $15,0002024-09-10
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-03-20
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-02-13
Virginia Foxx🏢 House$MO▼ Sell$1,001 - $15,0002024-01-16
Virginia Foxx🏢 House$MO▲ Buy$1,001 - $15,0002024-01-11
Ro Khanna🏢 House$MO▼ Sell$1,001 - $15,0002024-01-10
Ro Khanna🏢 House$MO▲ Buy$1,001 - $15,0002024-01-10
Virginia Foxx🏢 House$MO▼ Sell$15,001 - $50,0002024-01-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMTEMMO
Forward yield2000000.06%6.27%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$4.8792278646347776e+39M$77.7K
Annual income after 10y$4,878,748,002,861,388,000,000,000,000,000,000,000,000,000,000.00$28,968.54
Total dividends collected$4.8791964691115763e+39M$72.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: MTEM vs MO ($10,000, DRIP)

YearMTEM PortfolioMTEM Income/yrMO PortfolioMO Income/yrGap
1← crossover$200,010,706$200,000,006.00$10,558$768.31+$200.00MMTEM
2$3,738,731,992,770$3,738,517,981,314.42$11,352$1,015.87+$3738731.98MMTEM
3$65,315,068,744,949,500$65,311,068,301,717,240.00$12,482$1,367.86+$65315068744.94MMTEM
4$1,066,400,958,023,135,400,000$1,066,331,070,899,578,300,000.00$14,103$1,883.39+$1066400958023135.38MMTEM
5$16,272,185,237,131,282,000,000,000$16,271,044,188,106,197,000,000,000.00$16,472$2,664.91+$16272185237131282432.00MMTEM
6$232,054,281,880,765,440,000,000,000,000$232,036,870,642,561,700,000,000,000,000.00$20,024$3,897.79+$2.3205428188076545e+23MMTEM
7$3,092,799,715,549,616,000,000,000,000,000,000$3,092,551,417,468,003,600,000,000,000,000,000.00$25,537$5,933.74+$3.0927997155496157e+27MMTEM
8$38,524,114,942,504,994,000,000,000,000,000,000,000$38,520,805,646,809,356,000,000,000,000,000,000,000.00$34,478$9,476.77+$3.8524114942504996e+31MMTEM
9$448,468,947,092,778,960,000,000,000,000,000,000,000,000$448,427,726,289,790,500,000,000,000,000,000,000,000,000.00$49,776$16,022.63+$4.4846894709277894e+35MMTEM
10$4,879,227,864,634,777,500,000,000,000,000,000,000,000,000,000$4,878,748,002,861,388,000,000,000,000,000,000,000,000,000,000.00$77,699$28,968.54+$4.8792278646347776e+39MMTEM

MTEM vs MO: Complete Analysis 2026

MTEMStock

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Full MTEM Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this MTEM vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MTEM vs SCHDMTEM vs JEPIMTEM vs OMTEM vs KOMTEM vs MAINMTEM vs PMMTEM vs BTIMTEM vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.